Economic Evaluation under Ambiguity and Structural Uncertainties
Author
Abstract
Suggested Citation
Download full text from publisher
References listed on IDEAS
- Charles F. Manski, 2017. "Mandating vaccination with unknown indirect effects," Journal of Public Economic Theory, Association for Public Economic Theory, vol. 19(3), pages 603-619, June.
- Charles F. Manski, 2019. "Treatment Choice With Trial Data: Statistical Decision Theory Should Supplant Hypothesis Testing," The American Statistician, Taylor & Francis Journals, vol. 73(S1), pages 296-304, March.
- Charles F. Manski, 2018. "Reasonable patient care under uncertainty," Health Economics, John Wiley & Sons, Ltd., vol. 27(10), pages 1397-1421, October.
- Charles F. Manski, 2009. "The 2009 Lawrence R. Klein Lecture: Diversified Treatment Under Ambiguity," International Economic Review, Department of Economics, University of Pennsylvania and Osaka University Institute of Social and Economic Research Association, vol. 50(4), pages 1013-1041, November.
- Charles F. Manski, 2018. "Response to commentaries on “Reasonable patient care under uncertainty”," Health Economics, John Wiley & Sons, Ltd., vol. 27(10), pages 1431-1434, October.
- Garber, Alan M., 2000. "Advances in cost-effectiveness analysis of health interventions," Handbook of Health Economics, in: A. J. Culyer & J. P. Newhouse (ed.), Handbook of Health Economics, edition 1, volume 1, chapter 4, pages 181-221, Elsevier.
- Drummond, Michael F. & Sculpher, Mark J. & Claxton, Karl & Stoddart, Greg L. & Torrance, George W., 2015. "Methods for the Economic Evaluation of Health Care Programmes," OUP Catalogue, Oxford University Press, edition 4, number 9780199665884.
- Peter Ghijben & Yuanyuan Gu & Emily Lancsar & Silva Zavarsek, 2018. "Revealed and Stated Preferences of Decision Makers for Priority Setting in Health Technology Assessment: A Systematic Review," PharmacoEconomics, Springer, vol. 36(3), pages 323-340, March.
- Nancy Devlin & David Parkin, 2004. "Does NICE have a cost‐effectiveness threshold and what other factors influence its decisions? A binary choice analysis," Health Economics, John Wiley & Sons, Ltd., vol. 13(5), pages 437-452, May.
Most related items
These are the items that most often cite the same works as this one and are cited by the same works as this one.- Anirban Basu, 2018. "Comment: Manski's views on patient care under uncertainty," Health Economics, John Wiley & Sons, Ltd., vol. 27(10), pages 1422-1424, October.
- Neil Christy & A. E. Kowalski, 2024. "Starting Small: Prioritizing Safety over Efficacy in Randomized Experiments Using the Exact Finite Sample Likelihood," Papers 2407.18206, arXiv.org.
- Manski, Charles F., 2023.
"Probabilistic prediction for binary treatment choice: With focus on personalized medicine,"
Journal of Econometrics, Elsevier, vol. 234(2), pages 647-663.
- Charles F. Manski, 2021. "Probabilistic Prediction for Binary Treatment Choice: with Focus on Personalized Medicine," NBER Working Papers 29358, National Bureau of Economic Research, Inc.
- Charles F. Manski, 2021. "Probabilistic Prediction for Binary Treatment Choice: with focus on personalized medicine," Papers 2110.00864, arXiv.org.
- Charles F. Manski, 2018. "Reasonable patient care under uncertainty," Health Economics, John Wiley & Sons, Ltd., vol. 27(10), pages 1397-1421, October.
- Charles F. Manski, 2022.
"Patient‐centered appraisal of race‐free clinical risk assessment,"
Health Economics, John Wiley & Sons, Ltd., vol. 31(10), pages 2109-2114, October.
- Charles F. Manski, 2021. "Patient-Centered Appraisal of Race-Free Clinical Risk Assessment," Papers 2112.01639, arXiv.org, revised Feb 2022.
- Per Magnus Mæhle & Ingrid Kristine Small Hanto & Sigbjørn Smeland, 2020. "Practicing Integrated Care Pathways in Norwegian Hospitals: Coordination through Industrialized Standardization, Value Chains, and Quality Management or an Organizational Equivalent to Improvised Jazz," IJERPH, MDPI, vol. 17(24), pages 1-32, December.
- Charles F. Manski, 2023.
"Using Limited Trial Evidence to Credibly Choose Treatment Dosage when Efficacy and Adverse Effects Weakly Increase with Dose,"
NBER Working Papers
31305, National Bureau of Economic Research, Inc.
- Charles F. Manski, 2023. "Using Limited Trial Evidence to Credibly Choose Treatment Dosage when Efficacy and Adverse Effects Weakly Increase with Dose," Papers 2305.17206, arXiv.org.
- Kasper M. Johannesen & Karl Claxton & Mark J. Sculpher & Allan J. Wailoo, 2018. "How to design the cost‐effectiveness appraisal process of new healthcare technologies to maximise population health: A conceptual framework," Health Economics, John Wiley & Sons, Ltd., vol. 27(2), pages 41-54, February.
- Greve, Jane & Kristensen, Søren Rud & Lydiksen, Nis, 2023. "Patient and peer: Guideline design and expert response," Journal of Health Economics, Elsevier, vol. 92(C).
- John Mullahy, 2018. "Treatment Effects with Multiple Outcomes," NBER Working Papers 25307, National Bureau of Economic Research, Inc.
- Amanda Dahlstrand, 2022. "Defying distance? The provision of services in the digital age," CEP Discussion Papers dp1889, Centre for Economic Performance, LSE.
- John Mullahy, 2021. "Discovering treatment effectiveness via median treatment effects—Applications to COVID‐19 clinical trials," Health Economics, John Wiley & Sons, Ltd., vol. 30(5), pages 1050-1069, May.
- Julio Emilio Marco-Franco & Pedro Pita-Barros & Silvia González-de-Julián & Iryna Sabat & David Vivas-Consuelo, 2021. "Simplified Mathematical Modelling of Uncertainty: Cost-Effectiveness of COVID-19 Vaccines in Spain," Mathematics, MDPI, vol. 9(5), pages 1-15, March.
- Kitagawa, Toru & Wang, Guanyi, 2023. "Who should get vaccinated? Individualized allocation of vaccines over SIR network," Journal of Econometrics, Elsevier, vol. 232(1), pages 109-131.
- Juerg Schweri, 2021. "Predicting polytomous career choices in healthcare using probabilistic expectations data," Health Economics, John Wiley & Sons, Ltd., vol. 30(3), pages 544-563, March.
- Luca Panzone & Guy Garrod & Felice Adinolfi & Jorgelina Di Pasquale, 2022. "Molecular marketing, personalised information and willingness‐to‐pay for functional foods: Vitamin D enriched eggs," Journal of Agricultural Economics, Wiley Blackwell, vol. 73(3), pages 666-689, September.
- Valentyn Litvin, 2020. "When ignorance is bliss: Intentional agnosticism in drug approval," Health Economics, John Wiley & Sons, Ltd., vol. 29(2), pages 185-194, February.
- Dahlstrand Rudin, Amanda, 2022. "Defying distance? The provision of services in the digital age," LSE Research Online Documents on Economics 118042, London School of Economics and Political Science, LSE Library.
- Brekke, Kurt R. & Dalen, Dag Morten & Straume, Odd Rune, 2023. "The price of cost-effectiveness thresholds under therapeutic competition in pharmaceutical markets," Journal of Health Economics, Elsevier, vol. 90(C).
- Praveen Thokala & Jessica Ochalek & Ashley A. Leech & Thaison Tong, 2018. "Cost-Effectiveness Thresholds: the Past, the Present and the Future," PharmacoEconomics, Springer, vol. 36(5), pages 509-522, May.
More about this item
Keywords
ambiguity; structural uncertainty; economic evaluation; cost-effectiveness; cost-benefit analysis; healthcare technology assessment; regulation;All these keywords.
JEL classification:
- D70 - Microeconomics - - Analysis of Collective Decision-Making - - - General
- D81 - Microeconomics - - Information, Knowledge, and Uncertainty - - - Criteria for Decision-Making under Risk and Uncertainty
- H40 - Public Economics - - Publicly Provided Goods - - - General
- I18 - Health, Education, and Welfare - - Health - - - Government Policy; Regulation; Public Health
- O38 - Economic Development, Innovation, Technological Change, and Growth - - Innovation; Research and Development; Technological Change; Intellectual Property Rights - - - Government Policy
NEP fields
This paper has been announced in the following NEP Reports:- NEP-UPT-2023-11-20 (Utility Models and Prospect Theory)
Statistics
Access and download statisticsCorrections
All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:ris:albaec:2023_009. See general information about how to correct material in RePEc.
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Joseph Marchand (email available below). General contact details of provider: https://edirc.repec.org/data/deualca.html .
Please note that corrections may take a couple of weeks to filter through the various RePEc services.